AI takes on breast cancer: could a computer predict the best second treatment?

NCT ID NCT07227233

First seen Nov 12, 2025 · Last updated May 16, 2026 · Updated 22 times

Summary

This study tests whether an artificial intelligence model can identify patients with advanced HR+ HER2- breast cancer who might benefit from a second CDK4/6 inhibitor after the first one stops working. About 105 participants will either receive a second CDK4/6 inhibitor plus fulvestrant or the doctor's choice of therapy. The goal is to see if the AI-guided treatment delays tumor growth better than standard care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Diego

    RECRUITING

    La Jolla, California, 92093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.